Guggenheim Initiates Coverage On NewAmsterdam Pharma with Buy Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay has initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating and set a price target of $30.
January 18, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim has initiated coverage on NewAmsterdam Pharma with a Buy rating and a price target of $30, which could positively influence the stock's performance.
Analyst ratings, especially from reputable firms like Guggenheim, can significantly impact a stock's short-term performance. A Buy rating combined with a price target that suggests substantial upside can lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100